IRCT20200623047902N9已完成未知
Bioequivalence study of Ticagrelor 90 ( Brelor)manufactured by Kimia Ara Heram versus originator brand in healthy volunteers in fasting condition
Kimia Ara Heram company0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 50 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Ticagrelor
研究者
相似试验
尚未招募
Unknown
Comparative in vivo evaluation of 2 Ticagrelor 90 mg F.C. Tablet and Brilinta® 90 mg F.C. Tablet formulations.ong term (current) use of antithrombotics/antiplatelets.Long term (current) use of antithrombotics/antiplateletsZ79.02IRCT20180620040164N54Zist Arvand Pharme Ltd.24
招募中
不适用
In-vivo Bioequivalence Test of Ticagrelor® tablet with brand drugs (BRILINTA® AstraZeneca UK).IRCT20200105046010N28ARENA Pharmaceutical Company24
尚未招募
不适用
In vivo Bioequivalence study of Ticagrelor TabletIn the present study, no diseases will be examined and products will be administered by healthy volunteers..IRCT20210519051345N1Tabriz University of Medical Sciences24
招募中
不适用
In-vivo Bioequivalence Test of Ticagrelor® tablet with brand drugs (BRILINTA® AstraZeneca UK).IRCT20200105046010N31ABIDI Pharmaceutical Company24
尚未招募
1 期
Bioequivalence of TrienorHealthy volunteersHealthy VolunteersRPCEC00000265Center for Pharmaceutical Research and Development, Havana, Cuba.72